Further concerns have been expressed at the US Food and Drug Administration proposals for the labeling of generic drugs.
The FDA first put forward its Proposed Rule, which would allow generic companies to independently update safety warnings – something which only brand-name can currently do before receiving regulatory permission - in November 2013.
The agency has faced a major backlash from consumer and industry groups, and has twice delayed the rule’s publication date. The latest planned date for this is July 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze